Cookies Policy

The website of the University of Cádiz uses its own and third-party cookies to carry out analysis of use and measurement of traffic, as well as to allow the correct functioning in social networks, and in this way to improve your browsing experience.

If you want to configure cookies, press the button Customize Cookies. You can also access the cookie settings at any time from the corresponding link in the footer.

For more information about cookies you can consult the Cookies policy from the website of the University of Cádiz.

Cookies customization

The website of the University of Cádiz uses its own and third-party cookies to carry out analysis of use and measurement of traffic, as well as to allow the correct functioning in social networks, and in this way to improve your browsing experience.

For more information about cookies you can consult the Cookies policy from the website of the University of Cádiz. You can also access the cookie settings at any time from the corresponding link in the footer.

You can configure the website cookies according to their purpose:

  • Statistical analysis

    Third-party cookies (Google Analytics) are used on this site that allow the number of users to be quantified anonymously (personal data will never be obtained to identify the user) and thus be able to analyze the use made by users of our service, in order to improve the browsing experience and offer our content optimally.

  • Social networks

    Third-party cookies are used on this website that allow the proper functioning of some social networks (mainly YouTube and Twitter) without using any personal data of the user.

UniversidaddeCádiz
Desarrollo de scaffolds poliméricos mediante tecnología sol-gel para Ingenieria Tisular Osea

Rafael Fernández Montesinos

Doctor en Bioquímica por la Universidad de Sevilla. 

 

Participación en proyectos de investigación .- 

Sistemas nanoestructurados direccionados por el péptido intesinal vasoactivo (VIP) como alternativas para la detección y tratamiento de cáncer de próstata: caracterización preclínica
Investigador. Ministerio de Economía y Competitividad (Instituto de Salud Carlos III). PI14/01600

 

Desarrollo Preclínico del Eje de Neuropéptidos VIP/Adnp como Agentes Modificadores de Actividad Biológica de Células Madres de Médula Ósea en el Modelo Experimental de Esclerosis Lateral Amiotrófica. PROYECTOS DE EXCELENCIA, JUNTA DE ANDALUCÍA. P11-CTS-8161

 

Nuevas Terapias Antiparasitarias: Uso de Neuropéptidos Endógenos. PROYECTOS DE EXCELENCIA, JUNTA DE ANDALUCÍA. P09-CTS-4705

 

ESTUDIO DE LA CAPACIDAD INMUNOREGULADORA DEL PÉPTIDO INTESTINAL VASOACTIVO (VIP) SOBRE CÉLULAS MADRE DERIVADAS DE TEJIDO ADIPOSO (CMDA) EN EL MODELO PRECLÍNICO DE ESCLEROSIS MÚLTIPLE. FONDO DE INVESTIGACIÓN SANITARIA (FIS), MINISTERIO DE CIENCIA E INNOVACIÓN. PS09/02252

 

REALIZACIÓN DE PRUEBAS DE CONCEPTO PARA EL ESTUDIO DE LA ACTIVIDAD INMUNOMODULADORA DEL CONDROÍTIN SULFATO. 0541/0013

 

DISEÑO E IMPLANTACIÓN DE PROGRAMAS Y PROYECTOS DE INNOVACIÓN E INVESTIGACIÓN BIOMÉDICA DEL SISTEMA SANITARIO PÚBLICO DE ANDALUCIA. Fundación de Investigación de la US. 0014/0013

 

Construcción de genotecas de anticuerpos de cadena sencilla. Newbiotechnic, S.A. Contrato 68/83. SI-003/07

 

ESTUDIO PROSPECTIVO DEL USO TERAPÉUTICO COMO INMUNOMODULADOR DEL PÉPTIDO BIOACTIVO NAP.
Newbiotechnic, S.A. OTRI/05-FP02

 

ESTUDIO DE LOS EFECTOS DEL GEN ADNP Y PÉPTIDO NAP EN PATOLOGÍAS CON UN COMPONENTE INMUNITARIO. SUBV. ICAI

 

Participación en ensayos clínicos .-

 

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondaryprogressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study
Andalusian Initiative for Advanced Therapies – Fundación Pública Andaluza Progreso y Salud
CMM/EM/2008 y EudraCT 2008-004015-35
2009- 2015
https://clinicaltrials.gov/ct2/show/NCT01056471

 

Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis
Andalusian Initiative for Advanced Therapies – Fundación Pública Andaluza Progreso y Salud
CeTMMo/EM/2010 y EudraCT 2010-023368-42
2011-2016
https://clinicaltrials.gov/ct2/show/NCT01745783?term=NCT01745783&rank=1

 

A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral
Andalusian Initiative for Advanced Therapies – Fundación Pública Andaluza Progreso y Salud
CeTMAd/ELA/2011 y EudraCT 2011-006254-85
2012-2016
https://clinicaltrials.gov/ct2/show/NCT02290886?term=NCT02290886&rank=1

 

 Artículos .-

 

The use of melatonin as a vaccine agent.
Vaccine. 2005
Regodón S1, Martín-Palomino P, Fernández-Montesinos R, Herrera JL, Carrascosa-Salmoral MP, Píriz S, Vadillo S, Guerrero JM, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/16055232

 

The modulatory role of melatonin on immune responsiveness.
Curr Opin Investig Drugs. 2006
Carrillo-Vico A1, Reiter RJ, Lardone PJ, Herrera JL, Fernández-Montesinos R, Guerrero JM, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/16729718

 

Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice.
Ann N Y Acad Sci. 2006
Herrera JL1, Fernández-Montesinos R, González-Rey E, Delgado M, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/16888188

 

NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function.
Ann N Y Acad Sci. 2006
Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/16888216

 

Melatonin is a phytochemical in olive oil
Food Chemistry. 2007
Cristina de la Puerta, María P. Carrascosa-Salmoral, Pedro P. García-Luna, Patricia J. Lardone, Juan L. Herrera, Rafael Fernández-Montesinos, Juan M. Guerrero, David Pozo.
https://www.sciencedirect.com/science/article/pii/S0308814606009794

 

Alzheimer’s disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics.
J Cell Mol Med. 2008
Barba I1, Fernandez-Montesinos R, Garcia-Dorado D, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/18554316

 

Tiopronin monolayer-protected silver nanoparticles modulate IL-6 secretion mediated by Toll-like receptor ligands.
Nanomedicine (Lond). 2008
Castillo PM1, Herrera JL, Fernandez-Montesinos R, Caro C, Zaderenko AP, Mejías JA, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/18834270

 

Chaperone proteostasis in Parkinson’s disease: stabilization of the Hsp70/alpha-synuclein complex by Hip.
EMBO J. 2009
Roodveldt C1, Bertoncini CW, Andersson A, van der Goot AT, Hsu ST, Fernández-Montesinos R, de Jong J, van Ham TJ, Nollen EA, Pozo D, Christodoulou J, Dobson CM.
https://www.ncbi.nlm.nih.gov/pubmed/19875982

 

Chemical synthesis and characterization of silver-protected vasoactive intestinal peptide nanoparticles.
Nanomedicine (Lond). 2009
Fernandez-Montesinos R, Castillo PM, Klippstein R, Gonzalez-Rey E, Mejias JA, Zaderenko AP, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/19958228

 

Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages.
J Cell Mol Med. 2009
Herrera JL1, Gonzalez-Rey E, Fernandez-Montesinos R, Quintana FJ, Najmanovich R, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/20196778

 

Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer’s disease.
J Mol Neurosci. 2010
Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, Gutierrez A, Gozes I, Vitorica J, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/19844808

 

Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson’s disease-linked mutants.
PLoS One. 2010
Roodveldt C1, Labrador-Garrido A, Gonzalez-Rey E, Fernandez-Montesinos R, Caro M, Lachaud CC, Waudby CA, Delgado M, Dobson CM, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/21048992

 

Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation.
PLoS One. 2013
Roodveldt C1, Labrador-Garrido A, Gonzalez-Rey E, Lachaud CC, Guilliams T, Fernandez-Montesinos R, Benitez-Rondan A, Robledo G, Hmadcha A, Delgado M, Dobson CM, Pozo D.
https://www.ncbi.nlm.nih.gov/pubmed/24236103

 

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.
PLoS One. 2018
Fernández O, Izquierdo G, Fernández V1, Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo MD, Cuesta A, Soria B, Hmadcha A, Pozo D, Fernandez-Montesinos R, Leal M, Ochotorena I, Gálvez P, Geniz MA, Barón FJ,, Mata R, Medina C, Caparrós-Escudero C, Cardesa A, Cuende N; Research Group Study EudraCT 2008-004015-35.
https://www.ncbi.nlm.nih.gov/pubmed/29768414

 

Capítulos de libro .-

 

Silver Nanoparticles Interactions with the Immune System: Implications for Health and Disease
Silver Nanoparticles
IntechOpen / 2010
Rebecca Klippstein, Rafael Fernandez-Montesinos, Paula M. Castillo, Ana P. Zaderenko and David Pozo
https://www.intechopen.com/books/silver-nanoparticles/silver-nanoparticles-interactions-with-the-immune-system-implications-for-health-and-disease

 

The Occurrence of the Biogenic Amine Melatonin in Olive Oil: Implications in Health and Disease Prevention
Olives and Olive Oil in Health and Disease Prevention
Academic Press / 2010
Rafael Fernández-Montesinos, Cristina de la Puerta, Pedro P. García-Luna, Russel J.Reiter, David Pozo
https://www.sciencedirect.com/science/article/pii/B9780123744203000292?via%3Dihub

 

Patentes .-

 

UTILIZACIÓN DE NANOPARTÍCULAS DE METALES NOBLES COMO INMUNOMODULADORES Y COMPOSICIÓN INMUNOMODULADORA
UNIVERSIDAD DE SEVILLA, UNIVERSIDAD PABLO DE OLAVIDE
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2010037878
WO/2010/037878
08.04.2010

 

NANOPARTÍCULAS METÁLICAS FUNCIONALIZADAS CON EL NEUROPÉPTIDO VIP Y PROCEDIMIENTO DE PREPARACIÓN
UNIVERSIDAD DE SEVILLA, UNIVERSIDAD PABLO DE OLAVIDE
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009095516
WO/2009/095516
06.08.2009

 

USO DE LA MELATONINA COMO ADYUVANTE
UNIVERSIDAD DE SEVILLA, UNIVERSIDAD DE EXTREMADURA
https://patentscope.wipo.int/search/en/detail.jsf?docId=ES5616236&tab=NATIONALBIBLIO&_cid=P22-K37VZH-15198-1
200501542
2291074